A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

Inclusion Criteria

Patients must have:

• Documented HIV seronegativity.
• Negative HIV-1 culture.
• Normal history and physical exam.
• No high-risk behavior for HIV infection.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Clinically significant cardiac, pulmonary, neoplastic, hepatic, renal, neurologic, or autoimmune disease.
• Serologic evidence of current Hepatitis B or C infection.
• Positive PPD (unless subject has a clear chest x-ray with no suggestion of active or old pulmonary tuberculosis and is not eligible for tuberculosis prophylaxis.
• Positive HBsAb (unless positive result is caused by hepatitis vaccination OR infection occurred more than 2 years ago and subjects are HBsAg, HBeAg, and HBcAb negative with no elevation of liver enzymes within the past 2 years).
• Positive VDRL.
• Febrile illness within 1 week prior to study entry.

Concurrent Medication:

Excluded:

• Concomitant corticosteroids or other known immunosuppressive drugs.
• Any experimental agent.
• Any anti-tuberculosis medication (e.g., isoniazid).

Patients with the following prior conditions are excluded:

• History of clinically significant cardiac, pulmonary, neoplastic, hepatic, renal, neurologic, or autoimmune disease.
• Recent (within past 2 years) evidence of Hepatitis B infection.
• Past serologic evidence of Hepatitis C infection.
• Prior history of receiving HIV vaccine.

Prior Medication:

Excluded:

• Other immunization within 4 weeks prior to study entry.

Identifiable high-risk behavior for HIV infection.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety